Symbiomix Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 11
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $150M
Latest Deal Amount

Symbiomix Therapeutics General Information

Description

Developer of antibiotic drug intended to bring innovative medicines to market for preventing gynecologic infections. The company's antibiotic drug is a potent, next-generation, 5-nitroimidazole medicine with enhanced pharmacokinetic properties that makes efficacious and well tolerated delivery in a single dose, enabling patients to get treated from bacterial vaginosis.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Parent Company
Primary Office
  • 105 Lock Street
  • Suite 409
  • Newark, NJ 07103
  • United States
+1 (609) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Symbiomix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 11-Oct-2017 $150M 0000 00000 Completed Generating Revenue
3. Early Stage VC 03-May-2016 000 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 06-May-2015 $41M $41M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Symbiomix Therapeutics’s complete valuation and funding history, request access »

Symbiomix Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Helen Pentikis Ph.D Chief Scientific Officer
Taunia Markvicka Chief Commercial Officer
David Palling Ph.D Chief Manufacturing Officer
Joseph Amprey Ph.D Chief Business Officer and Co-Founder
Nikki Adetoro Vice President, Clinical Operations and Project Management
You’re viewing 5 of 13 executive team members. Get the full list »

Symbiomix Therapeutics Board Members (7)

Name Representing Role Since
Karen Dawes Self Board Member 000 0000
You’re viewing 1 of 7 board members. Get the full list »

Symbiomix Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Symbiomix Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Eight Roads Venture Capital Minority 000 0000 000000 0
Enterprise Development Center Accelerator/Incubator Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »